XML 102 R88.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Revenue $ 178,957 $ 170,276 $ 185,308
Cost of revenue 72,080 75,553 57,909
Research and development 102,953 122,117 141,756
Sales and marketing 84,759 88,579 95,603
General and administrative 72,806 83,934 88,527
Adjusted EBITDA [1] (80,371) (116,413) (121,589)
Operating Segments | MRD      
Segment Reporting Information [Line Items]      
Revenue 145,529 102,739 87,144
Cost of revenue 64,177 63,273 42,606
Research and development 40,743 42,153 31,768
Sales and marketing 77,579 76,742 65,558
General and administrative 40,446 46,961 32,349
Items to reconcile net loss to adjusted EBITDA [1] 39,012 37,546 24,641
Adjusted EBITDA [1] (41,223) (88,844) (60,496)
Operating Segments | IM      
Segment Reporting Information [Line Items]      
Revenue 33,428 67,537 98,164
Research and development 62,210 79,964 109,988
Items to reconcile net loss to adjusted EBITDA [1] 31,619 33,366 36,186
Adjusted EBITDA [1] (26,005) (14,128) (45,654)
Unallocated Corporate      
Segment Reporting Information [Line Items]      
Adjusted EBITDA [1] (13,143) (13,441) (15,439)
Unallocated Corporate | MRD      
Segment Reporting Information [Line Items]      
Other segment items [2] 2,819 0 0
Unallocated Corporate | IM      
Segment Reporting Information [Line Items]      
Other segment items [3] $ 28,842 $ 35,067 $ 70,016
[1] Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.
[2] Includes MRD impairment of long-lived assets expenses.
[3] Includes all Immune Medicine operating expenses, other than research and development expenses.